The drug, bivamelagon, was tested in a mid-stage trial to treat patients with acquired hypothalamic obesity, caused by damage to the brain's hypothalamus.

Dr Alka Jha further adds, "It suppresses natural testosterone production by down-regulating the ...

Eating disorders are among the deadliest psychological disorders, but there are no approved medical interventions for them – yet.

Setmelanotide was associated with significant weight reduction among patients aged 4 years and older with acquired hypothalamic obesity.

SAN FRANCISCO — In patients with acquired hypothalamic obesity, setmelanotide reduced BMI at 52 weeks compared with placebo, according to results of the TRANSCEND trial presented at ENDO ...

An oral MC4R agonist conferred reductions in BMI for adolescents and adults with hypothalamic obesity that were similar to what has been observed with subcutaneous setmelanotide.

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.

Acquired hypothalamic obesity is a severe and debilitating condition caused by hypothalamic damage, often resulting from brain tumors, their treatment or other injuries.

Rhythm Pharmaceuticals, Inc.'s IMCIVREE and new oral MC4R agonist, bivamelagon, show strong efficacy in rare obesity disorders, especially hypothalamic obesity (HO). HO represents a blockbuster ...

Rhythm Pharma (RYTM) stock gains as the company's experimental therapy bivamelagon shows promise in Phase 2 trial for rare acquired hypothalamic obesity. Read more here.

New data from Rhythm Pharmaceuticals show significant BMI reductions in acquired hypothalamic obesity with setmelanotide and bivamelagon treatments.

Shares of Rhythm Pharmaceuticals RYTM were up 36.6% yesterday after it reported positive top-line data from a phase II study evaluating the investigational oral melanocortin-4 receptor (MC4R) agonist, ...